A Single Blood Test For All Cancers? Illumina’s GRAIL

Here’s the story in Forbes:

“What if a simple blood test could detect any cancer early, when it was still easy to treat?

It sounds like science fiction. But Illumina ILMN -0.61%, the $24 billion (market cap) biotechnology company that has pioneered cheap, efficient sequencing of DNA, says it could be a reality in a few years. It is launching a new startup, GRAIL (because such a test would be a holy grail for cancer doctors), with $100 million in funding.”